68ga-dota-fapi
Small moleculeexperimentalImaging agent
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2020 (NCT04554719)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 68-gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06659705 | Phase 2 | Jan 30, 2025 | Curie Institute |
| NCT06455761 | Early Phase 1 (Phase 1) | Apr 1, 2024 | Fujian Medical University |
| NCT05990998 | Phase 1/Phase 2 (Phase 2) | Nov 20, 2022 | Fujian Medical University |
| NCT05400967 | Early Phase 1 (Phase 1) | Jan 1, 2022 | Chinese Academy of Medical Sciences |
| NCT05030597 | N/A | Sep 15, 2021 | Xiamen University |
| NCT04849247 | Phase 1 | Apr 13, 2021 | Xiamen University |
| NCT04554719 | N/A | May 22, 2020 | Huazhong University of Science and Technology |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fujian Medical University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Xiamen University | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Curie Institute | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1